Study of an investigational drug for active thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new medicine called MHB018A for people with active thyroid eye disease (TED), a condition that causes the eyes to bulge and become inflamed. The study aims to see if the drug can reduce symptoms and improve eye appearance compared to a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You weigh 120 kg (about 264 lbs) or less.
- You have been diagnosed with active, moderate-to-severe thyroid eye disease (proptosis, eyelid retraction, or pain) that started within the last 12 months.
- Your eye symptoms score at least 3 out of 7 on a standard scale at the start of the study.
- You do not need immediate eye surgery or radiation therapy for your condition.
- If you have diabetes, it must be well-controlled and stable.
- You have not had certain prior treatments (e.g., steroids, immunosuppressants, radioiodine, botox around the eyes, or any investigational drug) recently.
- You do not have significant heart rhythm problems, uncontrolled high blood pressure, hearing issues, inflammatory bowel disease, or active infections like hepatitis, HIV, syphilis, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for people with long-term thyroid eye disease that has lasted over a year. The aim is to see if it can reduce symptoms like bulging and discomfort.
This study tests a longer-term use of MHB018A for people with thyroid eye disease who did not fully respond to treatment in a previous study. It aims to see if further treatment can help improve eye bulging and other symptoms.
This study offers continued treatment with an investigational drug for people who completed a prior clinical trial for thyroid eye disease but still have bulging eyes (proptosis) or experienced a relapse. The goal is to provide ongoing care and monitor safety and effectiveness.
This study tests an investigational medication for thyroid eye disease, which causes bulging eyes and discomfort. The treatment is given as an injection near the eye, and the study will last about 12 months to see how safe and effective it is.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
This study tests an experimental pill (linsitinib) for people with active thyroid eye disease. Participation may help reduce eye bulging and other symptoms, especially if other treatments haven't worked.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.